Navigation Links
Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes
Date:8/26/2014

SAN DIEGO, Aug. 26, 2014 /PRNewswire/ -- Profil Institute for Clinical Research, Inc., an early phase clinical research organization (CRO) focused on diabetes and obesity, announced today a milestone in clinical research for diabetes with the completion of more than 200 phase I – IIa clinical trials encompassing every clinically relevant drug class for the treatment of type 1 and type 2 diabetes.  

"The significance of this vast amount of research is what it represents for the public domain," said Dan Bradbury, former Amylin Pharmaceutical CEO, managing member of BioBrit, LLC, and member of Profil Institute's Board of Directors.  "Science driven results, as well as advances in clinical research methodologies by Profil Institute have contributed substantially to our understanding of new treatment opportunities and of how early phase clinical research in diabetes and obesity can be conducted in the most meaningful and efficient way.  As a result, we've seen significant progress toward better treatments for both type 1 and type 2 diabetes."

"The sense of urgency related to the diabetes epidemic is increasing with the rapid global rise of diabetes," said Dr. Marcus Hompesch, Profil Institute CEO.  "We've contributed important research to many current therapies providing exciting new treatment options for patients, but we have to continue to outpace ourselves to make an impact on diabetes worldwide.  We a have long, yet promising, path of opportunities in metabolic research as we turn our attention to biomarker discovery to predict and support the treatment of cardiometabolic diseases, as well as looking at novel combination therapies using existing drugs.

"More than a decade ago we decided to focus on diabetes, obesity and cardiometabolic clinical research because, as a group of scientists, that was at the center of our research and was where we hoped to make the most significant impact on science and patient care.  Today we're pleased that through our commitment to science, clinical research and drug development, we have built the teams, infrastructure, technology and expertise that have allowed us to accumulate the knowledge and experience to benefit diabetes research as a whole."

Profil Institute is the only CRO in the U.S. therapeutically and scientifically focused exclusively on early phase diabetes and obesity clinical research and development.  Profil Institute has invested in its scientific expertise, including doctorate level scientists that make up more than 20% of Profil Institute's workforce, and in advancing its Automated Glucose Clamp technology and other key research methods.  The company's experience in early phase clinical studies includes every clinical relevant drug class, as well as nearly all modes of administration and blood glucose monitoring devices.  Of the 200 early phase clinical studies completed, 45% of those studies involved study participants with type 2 diabetes, 20% with type 1 diabetes, 20% with healthy study participants, and 15% involved specialized populations, including participants with cardiovascular disease, kidney disease or insulin resistance.

About Profil Institute for Clinical Research, Inc.

Profil Institute for Clinical Research, Inc. is a science driven, early phase clinical research organization (CRO) focused on diabetes and obesity.  It is renowned for its scientific expertise, depth of services, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes.  The company provides end-to-end early phase services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.

Profil Institute's expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices.  The company's clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia. 

Profil Institute is also recognized internationally as an innovator of methodologies to improve the quality of metabolic research, including its Automated Glucose Clamp technology.  As the leading early phase CRO focused on diabetes and obesity, Profil Institute is driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners  and its Metabolic Research Partners™ program. 

For more information, please visit www.profilinstitute.com.


'/>"/>
SOURCE Profil Institute for Clinical Research, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
2. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
3. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
4. Abaxis Announces the Launch of Kidney Profile Plus Panel
5. NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study
6. Group Florence Nightingale Increases Radiosurgery Profile with Acquisition of Turkeys First Leksell Gamma Knife Perfexion System
7. Varian Medical Systems Selected by Leading Russian Development Foundations to Take Part in High-Profile Supplier Event
8. Medical Devices Research: Country Reports on Market Profile, Competitive Environment and more at RnRMarketResearch.com
9. High Profile HealthCare Companies: Leading Pharma Company Secures New Patents
10. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
11. Fortune Magazine Profiles ArcView Group, Co-founded by Steve DeAngelo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... New Zealand , May 24, 2016 ... and informatics solutions for the healthcare sector, has been named ... New Zealand Hi-Tech Awards 2016. Dr Bruce ... fantastic acknowledgement for our team.  It,s really good to be ... burden healthcare internationally. Our products are used in 35 countries ...
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
(Date:5/23/2016)... , May 23, 2016 ... Handling Equipment Market by Product (Wheelchair, Scooters, Medical ... (Bariatric Care, Critical Care, Wound), Accessories (Lifting, Transfer) ... to 2021", published by MarketsandMarkets, the patient handling ... Billion by 2021 at a CAGR of 10.5% ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National ... Science® and international water advocate, was honored by Ashram, Inc. as the world’s foremost ... who knelt on the banks of the Nile to fill their red clay pots ...
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our ... PROTECTION TO YOUR HEAD ™”. , “We are proud to introduce Meghan ... football front we have Brian Quick, wide receiver for Los Angeles who was a ...
(Date:5/26/2016)... ... 26, 2016 , ... Metcalf & Associates’ Maureen Metcalf ... experience in leading technology and human resources operations for health care, education, banking, ... be featured on Metcalf’s VoiceAmerica radio show , Innovative Leaders Driving Thriving ...
(Date:5/26/2016)... , ... May 26, 2016 , ... May 2016 – ... so central to popular cosmetic improvement efforts. Record numbers of clients now ask about ... prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... is happy to announce the launch of its brand equity product, Brandvantage. ... to reflect the dynamic landscape of modern consumer decision-making. The proprietary framework ...
Breaking Medicine News(10 mins):